Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for sinus tachycardia in septic shock
ACTRN12618001675213Phase 3Not yet recruiting
- Sponsor
- Monash Medical Centre
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ivabradine in septic shock (2 arms), sponsored by Monash Medical Centre. Primary endpoint: Heart rate response. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
ivabradine
03
Conditions
septic shock
Beyond the preview
Go deeper on ACTRN12618001675213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001675213.